CELZ NASDAQ Week ended 07 Aug 2026

Weekly Investor Report

Creative Medical Technology Holdings Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 1.42 USD
113.9% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is -22.7% below the Trend Line and sits at 14.2% of its 52-week range. The latest completed week returned 113.9%, after a 55.7% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 60/100. Near-term considerations: earnings are due in 1d.

Setup score 40 out of 100
Latest Close 1.42 USD 7 Aug 2026
1W Return 113.9% latest completed week
4W Return 55.7% short-term follow-through
12W Return -36.6% quarterly tape
Trend Breadth 21.2% 11 of 52 weeks active
Volume Ratio 8.5x vs 13-week average
What is working
  • Volume is elevated versus the 13-week average, confirming attention.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 113.9% Latest completed week; four-week move 55.7%. Indicator stack 12/23 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 60/100 56 relevant articles in the latest sentiment read. Event risk 1d Next report is scheduled for 14 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -22.7% below the Trend Line and sits at 14.2% of its 52-week range. The latest completed week returned 113.9%, after a 55.7% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 8.5x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1212-week average 0.24

12-week confirmation

Trend active1/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure6/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.12Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 55.7% over four weeks, -36.6% over 12 weeks, and -57.4% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W113.9%
4W55.7%
12W-36.6%
26W-26.4%
52W-57.4%
Active trend streak0 weeks
Active weeks in one year11
Trend breadth21.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.98Latest activity-pressure read.
Pressure change-114.6%Four-week change in activity pressure.
Leadership-47.47Latest relative-leadership reading.
RS change31.0%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 82% Model confidence 77%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength67/100Blend of value, momentum, and quality. Underlying universe rank 34; rank 1 is best.
Value59/100Relative valuation strength. Underlying universe rank 42; rank 1 is best.
Quality56/100Profitability and accounting quality. Underlying universe rank 45; rank 1 is best.
Momentum58/100Medium-term price momentum. Underlying universe rank 43; rank 1 is best.
Growth58/100Revenue and earnings growth. Underlying universe rank 43; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
3070.5x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-154.9%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-2955.0%
Gross profit retained from each unit of revenue.
Operating margin
-195805.7%
Operating profit retained from revenue.
Free-cash-flow margin
-182107.1%
Free cash flow generated from revenue.
Return on invested capital
-1099.8%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-78.6%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-77.9%
Net share repurchases relative to market value.
Shareholder yield
-77.9%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.0x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment60/100

Weighted news tone is positive across 56 relevant articles.

19 positive · 29 neutral · 8 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings1dNext report is scheduled for 14 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-77.3%Distance below the 52-week high.
13-week volatility35.4%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2613 weeks finished lower.
Best week+113.9%Week of 7 Aug.
Worst week-46.2%Week of 26 Jun.
Latest week+113.9%Week of 7 Aug.

Shape of recent returns

Strong gains7
Modest gains5
Flat weeks1
Modest losses5
Sharp losses8
Recent vol35.4%13-week weekly-return volatility.
Base vol19.8%52-week weekly-return volatility.
Up/down split22/29Count of positive and negative weeks in the 52-week window.
Average skew11.5% / -8.8%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape29/100

Trend, activity pressure, participation, and risk combine to a 29/100 tape read.

 Indicator analysis23/100

Latest 12-week confirmation: trend 1/12, activity pressure 6/12, relative leadership 0/12.

Activity pressure 0.12; No reversal markers Factors59/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 99 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment60/100

Weighted news tone is positive across 56 relevant articles.

Creative Medical Technology Holdings, Inc. (CELZ) stock price, news, quote and history Insiders50/100

No recent insider transaction evidence is stored.

 Earnings1d

Next report is scheduled for 14 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 20261.42 USD113.9%1.84 USD3.24 USD-0.98-47.47380.8MOff
31 Jul 20260.66 USD-18.0%1.87 USD3.27 USD-1.29-74.69931.9KOff
24 Jul 20260.81 USD-7.8%1.91 USD3.30 USD-1.16-69.59808.6KOff
17 Jul 20260.88 USD-3.6%1.95 USD3.33 USD-0.99-68.111.3MOff
10 Jul 20260.91 USD-24.6%1.99 USD3.36 USD-0.46-68.842.8MOff
3 Jul 20261.21 USD0.8%2.03 USD3.38 USD-0.05-58.70195.0MOff
26 Jun 20261.20 USD-46.2%2.07 USD3.41 USD0.27-59.291.0MOff
19 Jun 20262.23 USD2.8%2.12 USD3.43 USD0.61-28.78505.9KOn
12 Jun 20262.17 USD5.3%2.14 USD3.44 USD0.67-29.39111.4KOff
5 Jun 20262.06 USD-8.4%2.17 USD3.46 USD0.79-31.77393.3KOff
29 May 20262.25 USD-5.9%2.20 USD3.48 USD0.89-29.35187.2KOff
22 May 20262.39 USD6.7%2.23 USD3.50 USD0.94-23.18252.0KOff
15 May 20262.24 USD-3.0%2.32 USD3.52 USD0.90-27.34181.2KOff
8 May 20262.31 USD3.1%2.36 USD3.54 USD0.95-25.55269.4KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context